Condition (MeSH)
Aphakia, Postcataract
ClinicalTrials.gov lists 6 trials for Aphakia, Postcataract or a narrower condition beneath it. Beaver-Visitec International, Inc. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Aphakia, Postcataract itself; the rest are tagged with a narrower condition beneath it.
When did Aphakia, Postcataract trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Unknown
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2019 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 6 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Aphakia, Postcataract trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 5 |
| Unknown | 1 |
How many Aphakia, Postcataract trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Aphakia, Postcataract trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Beaver-Visitec International, Inc. | 3 |
| Kowa Research Institute, Inc. | 1 |
Which serious adverse events do Aphakia, Postcataract trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Retinal detachment | 6 | 1 |
| Vitrectomy | 4 | 1 |
| Macular hole | 3 | 1 |
| Cataract operation complication | 2 | 1 |
| Death | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Aphakia, Postcataract? (93)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Stereopsis in the Infant Aphakia Treatment Study: outcome at 10½ years. | Eye (London, England) | 2025 | Yes |
| Safety and efficacy in pediatric secondary intraocular lens implantation, in-the-bag versus sulcus implantation: a multicenter, single-blinded randomized controlled trial. | Trials | 2023 | Yes |
| In-the-Bag Versus Ciliary Sulcus Secondary Intraocular Lens Implantation for Pediatric Aphakia: A Prospective Comparative Study. | American journal of ophthalmology | 2022 | Yes |
| Myopic Shift at 10-Year Follow-up in the Infant Aphakia Treatment Study. | Ophthalmology | 2022 | Yes |
| Long-term strabismus outcomes after unilateral infantile cataract surgery in the Infant Aphakia Treatment Study. | Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus | 2022 | Yes |
Showing 5 of 93 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.